UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 11, 2019

 

KODIAK SCIENCES INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-38682

27-0476525

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

2631 Hanover Street

Palo Alto, CA

 

94304

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s telephone number, including area code: (650) 281-0850

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.0001

KOD

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 8.01. Other Events

On October 11, 2019, Kodiak Sciences Inc. (the “Company”) issued a press release announcing safety, efficacy and durability data from its ongoing Phase 1b study of its product candidate KSI-301 in patients with treatment-naïve wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

 

Description

 

 

99.1

 

Press Release dated October 11, 2019.

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

KODIAK SCIENCES INC.

 

 

 

 

Date: October 15, 2019

 

By:

/s/ Victor Perlroth

 

 

 

Victor Perlroth, M.D.

 

 

 

Chief Executive Officer

 

Kodiak Sciences (NASDAQ:KOD)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Kodiak Sciences Charts.
Kodiak Sciences (NASDAQ:KOD)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Kodiak Sciences Charts.